Search

Search Constraints

You searched for: Author/Creator Galmozzi, E.

Search Results

1. A genetic risk score predicts de novo hepatocellular carcinoma in hepatits c cirrhotic patients treated with direct-acting antivirals. (February 2020)

2. AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. (February 2019)

3. Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. Issue 1 (February 2018)

4. Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients. (February 2019)

5. Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated hbv cirrhotics treated with nuc for 10 years. (February 2020)

9. HLA DPB1 rs9277535 polymorphism strongly predicts HBsAg clearance in interferon treated genotype D HBeAg-negative patients with chronic hepatitis B. (15th February 2015)